TABLE 2.
Characteristics of treatment combination and outcome in patients stratified according to the presence of pneumonia at the time of COVID‐19 diagnosis
| Total | Pneumonia cohort | No pneumonia cohort | p‐value | |
|---|---|---|---|---|
| First treatment cycle in COVID‐19 positive patients, n (%) | 32 (100) | 18 (56) | 14 (44) | NA |
| Total length of remdesivir treatment, days, median; mean (range) | 5; 5.0 (NA) | 5; 5.0 (NA) | 5; 5.0 (NA) | 1.0 |
| Number of days between COVID‐19 diagnosis and remdesivir start, median; mean (range) | 1; 2.3 (0–11) | 1; 2.4 (0–10) | 1; 2.1 (0–11) | 0.912 |
| Total number of high‐titer CP administration, median; mean (range) | 2; 2.0 (2–3) | 2; 2.0 (NA) | 2; 2.1 (2–3) | 1.0 |
| Number of days between high‐titer CP administration and remdesivir start, median; mean (range) | 0; −0.25 (−5–1) | 0; −0.30 (−5–0) | 0; −0.20 (−4–1) | 0.803 |
| Concomitant corticosteroids use, n (%) | 15 (47) | 10 (56) | 5 (36) | 0.308 |
| Concomitant LMWH use, n (%) | 29 (91) | 18 (100) | 11 (79) | 0.073 |
| COVID‐19 highest degree of severity on treatment during first treatment cycle, n (%) | ||||
| Asymptomatic | 2 (6) | 0 (0) | 2 (14) | <0.001 |
| Mild | 8 (25) | 0 (0) | 8 (57) | |
| Moderate | 2 (6) | 2 (11) | 0 (0) | |
| Severe | 15 (47) | 11 (61) | 4 (29) | |
| Critical | 5 (16) | 5 (28) | 0 (0) | |
| Total length of hospitalization during first treatment cycle, median (range) | 13 (5–91) | 15 (6–91) | 12 (5–26) | 0.574 |
| Total number of treatment cycles, n | 44 | 27 | 17 | NA |
| Number of cycles per patient, median; mean (range) | 1; 1.4 (1–4) | 1; 1.5 (1–4) | 1; 1.2 (1–2) | 0.337 |
| Number of patients with 2nd cycle, n (%) | 9 (28) | 6 (33) a | 3 (21) | 0.694 |
| Number of patients with 3rd cycle, n (%) | 2 (6) | 2 (11) | 0 (0) | NA |
| Number of patients with 4th cycle, n (%) | 1 (3) | 1 (6) | 0 (0) | NA |
| Reason for retreatment, n (%) | ||||
| SARS‐CoV‐2 prolonged positivity | 8 (66) | 7 (78) | 1 (33) | 0.236 |
| Secondary prophylaxis | 2 (17) | 1 (11) | 1 (33) | 0.455 |
| SARS‐CoV‐2 re‐positivity (new positivity after negativity) | 2 (17) | 1 (11) | 1 (33) | 0.455 |
| SARS‐CoV‐2 culture performed during all treatment cycles, n (% ) | 8 (18) | 4 (15) | 4 (24) | 0.690 |
| Time from remdesivir start to sampling, days, median (range) | 6 (0–30) | 6 (0–18) | 7 (0–30) | NA |
| Positive SARS‐CoV‐2 culture, n (%) | 5 (63) | 4 (100) | 1 (25) | NA |
| Alive at the time of data cutoff, n (% ) | 29 (91) | 15 (83) | 14 (100) | 0.238 |
| Death attributed to COVID‐19, n (%) | 3 (100) | 3 (100) | NA | NA |
Note: The significance level p < 0.05 is depicted in bold.
Abbreviations: COVID‐19, coronavirus disease 2019; CP, convalescent plasma, LMWH, low molecular weight heparin; SARS‐CoV‐2, severe acute respiratory syndrome‐related coronavirus‐2.
a
One patient received 10‐day remdesivir treatment.